Federal regulation, litigation and quality
- FDA, GLP-1 compounding policy: https://www.fda.gov/drugs/drug-alerts-and-statements/fda-clarifies-policies-compounders-national-glp-1-supply-begins-stabilize
- FDA, semaglutide shortage determination: https://www.fda.gov/media/185526/download
- FDA, proposed 503B bulks exclusions: https://www.fda.gov/news-events/press-announcements/fda-proposes-exclude-semaglutide-tirzepatide-and-liraglutide-503b-bulks-list
- Fifth Circuit, tirzepatide opinion: https://www.govinfo.gov/content/pkg/USCOURTS-ca5-25-10600/pdf/USCOURTS-ca5-25-10600-0.pdf
- Fifth Circuit, revised semaglutide opinion: https://www.ca5.uscourts.gov/opinions/unpub/25/25-10758.0.pdf
- FDA, statutory compounding comparison: https://www.fda.gov/drugs/human-drug-compounding/fdc-act-provisions-apply-human-drug-compounding
- FDA, 503A copying guidance: https://www.fda.gov/files/drugs/published/Compounded-Drug-Products-That-Are-Essentially-Copies-of-a-Commercially-Available-Drug-Product-Under-Section-503A-of-the-Federal-Food--Drug--and-Cosmetic-Act-Guidance-for-Industry.pdf
- FDA, 503A prescription guidance: https://www.fda.gov/media/97347/download
- Federal Register, outsourcing statutory framework: https://public-inspection.federalregister.gov/2023-07237.pdf
- FDA, outsourcing-facility information: https://www.fda.gov/drugs/human-drug-compounding/information-outsourcing-facilities
- FDA, outsourcing registration questions: https://www.fda.gov/drugs/human-drug-compounding/questions-and-answers-outsourcing-facility-registration
- FDA, compounding questions: https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers
- FDA, unapproved GLP-1 concerns: https://www.fda.gov/drugs/drug-alerts-and-statements/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss
- FDA, outsourcing register: https://www.fda.gov/drugs/human-drug-compounding/registered-outsourcing-facilities
- FDA, compounding inspection and recall records: https://www.fda.gov/drugs/human-drug-compounding/compounding-inspections-recalls-and-other-actions
- FDA, Form 483 explanation: https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/inspection-references/fda-form-483-frequently-asked-questions
- FDA, compounded semaglutide dosing errors: https://www.fda.gov/drugs/human-drug-compounding/fda-alerts-health-care-providers-compounders-and-patients-dosing-errors-associated-compounded
- FDA, wholesale distributor verification: https://www.fda.gov/drugs/drug-supply-chain-integrity/check-licensure-wholesale-drug-distributors-and-third-party-logistics-providers
- FDA, pharmacy DSCSA responsibilities: https://www.fda.gov/drugs/drug-supply-chain-security-act-dscsa/pharmacists-utilize-dscsa-requirements-protect-your-patients
- FDA, small-dispenser exemption extension: https://www.fda.gov/media/194424/download
- FDA, telehealth promotion guidance: https://www.fda.gov/drugs/human-drug-compounding/fda-telehealth-companies-what-know-when-promoting-compounded-drugs
Access programmes, products and purchasing
- LillyDirect FAQ: https://www.lilly.com/lillydirect/faq
- LillyDirect dispensing support: https://www.lilly.com/lillydirect/rx-support
- Zepbound professional savings terms: https://zepbound.lilly.com/hcp/coverage-savings
- NovoCare provider delivery information: https://www.novocare.com/hcp/delivery.html
- NovoCare delivery terms: https://www.novocare.com/eligibility/delivery.html
- Wegovy savings offers: https://www.novocare.com/patient/medicines/wegovy/savings-offer.html
- Foundayo savings terms: https://foundayo.lilly.com/coverage-savings
- FDA, Foundayo approval announcement: https://www.fda.gov/news-events/press-announcements/fda-approves-first-new-molecular-entity-under-national-priority-voucher-program
- Wegovy prescribing information: https://www.novo-pi.com/wegovy.pdf
- Zepbound prescribing information: https://pi.lilly.com/us/zepbound-uspi.pdf
- Lilly/Hims & Hers announcement, November 6, 2026: https://investor.lilly.com/node/55266/pdf
- McKesson account requests: https://mms.mckesson.com/content/request-an-account/
- McKesson pharmaceutical ordering: https://www.mckesson.com/pharmacy-technology/pharmaceutical-ordering/drug-returns/
Coverage, state requirements, privacy and remuneration
- CMS, Medicare GLP-1 Bridge coverage information: https://www.cms.gov/medicare/coverage/prescription-drug-coverage/medicare-glp-1-bridge/information-part-d-plans
- CMS, Bridge pharmacy instructions: https://www.cms.gov/files/document/glp-1-pharmacies-c.pdf
- CMS, Bridge prescriber instructions: https://www.cms.gov/files/document/glp-1-prescribers-c-1.pdf
- California, nonresident sterile-compounding application: https://www.pharmacy.ca.gov/forms/nrp_comp_app_pkt.pdf
- Texas, pharmacy licence categories: https://www.pharmacy.texas.gov/applicants/new-pharmacy.asp
- HHS, cross-state telehealth licensing: https://telehealth.hhs.gov/licensure/licensing-across-state-lines
- Arizona Board of Nursing, FDA multi-dose-vial advisory: https://azbn.gov/news/fda-safety-advisory-compounded-glp-1-multi-dose-vials
- HHS, treatment disclosures versus business associates: https://www.hhs.gov/hipaa/for-professionals/faq/do-i-need-a-business-associate-contract-to-disclose-information-to-a-provider/index.html
- HHS, business-associate contract provisions: https://www.hhs.gov/hipaa/for-professionals/covered-entities/sample-business-associate-agreement-provisions/index.html
- HHS OIG, fraud and abuse laws: https://oig.hhs.gov/compliance/physician-education/fraud-abuse-laws/
- California Pharmacy Lawbook, including section 650: https://www.pharmacy.ca.gov/laws_regs/lawbook.pdf?preview=true&site_id=816
Operational and industry discovery sources
- ASHP, medication-access coordinator template: https://www.ashp.org/-/media/assets/pharmacy-practice/resource-centers/specialty-pharmacy/Medication-Access-Coordinator.pdf
- Optum pharmacy-care coordinator posting: https://careers.unitedhealthgroup.com/job/jeffersonville/pharmacy-care-coordinator/34088/103216187584
- Everything GLP-1, compounding-industry interview description: https://shows.acast.com/everything-glp-1/episodes/scott-brunner-inside-the-regulatory-battle-shaping-compounde
- Independent Rx, webinar description: https://www.youtube.com/watch?v=T4JNCTma9NA
- Fierce Healthcare, November 6, 2026 partnership reporting, used for discovery and checked against the manufacturer announcement: https://www.fiercehealthcare.com/health-tech/hims-hers-inks-deal-eli-lilly-offer-branded-weight-loss-drugs
Sources cited on this page
- fda.gov · Source 1 ↗https://www.fda.gov/drugs/drug-alerts-and-statements/fda-clarifies-policies-compounders-national-glp-1-supply-begins-stabilize
- fda.gov · Source 2 ↗https://www.fda.gov/media/185526/download
- fda.gov · Source 3 ↗https://www.fda.gov/news-events/press-announcements/fda-proposes-exclude-semaglutide-tirzepatide-and-liraglutide-503b-bulks-list
- govinfo.gov · Source 4 ↗https://www.govinfo.gov/content/pkg/USCOURTS-ca5-25-10600/pdf/USCOURTS-ca5-25-10600-0.pdf
- ca5.uscourts.gov · Source 5 ↗https://www.ca5.uscourts.gov/opinions/unpub/25/25-10758.0.pdf
- fda.gov · Source 6 ↗https://www.fda.gov/drugs/human-drug-compounding/fdc-act-provisions-apply-human-drug-compounding
- fda.gov · Source 7 ↗https://www.fda.gov/files/drugs/published/Compounded-Drug-Products-That-Are-Essentially-Copies-of-a-Commercially-Available-Drug-Product-Under-Section-503A-of-the-Federal-Food--Drug--and-Cosmetic-Act-Guidance-for-Industry.pdf
- fda.gov · Source 8 ↗https://www.fda.gov/media/97347/download
- public-inspection.federalregister.gov · Source 9 ↗https://public-inspection.federalregister.gov/2023-07237.pdf
- fda.gov · Source 10 ↗https://www.fda.gov/drugs/human-drug-compounding/information-outsourcing-facilities
- fda.gov · Source 11 ↗https://www.fda.gov/drugs/human-drug-compounding/questions-and-answers-outsourcing-facility-registration
- fda.gov · Source 12 ↗https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers
- fda.gov · Source 13 ↗https://www.fda.gov/drugs/drug-alerts-and-statements/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss
- fda.gov · Source 14 ↗https://www.fda.gov/drugs/human-drug-compounding/registered-outsourcing-facilities
- fda.gov · Source 15 ↗https://www.fda.gov/drugs/human-drug-compounding/compounding-inspections-recalls-and-other-actions
- fda.gov · Source 16 ↗https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/inspection-references/fda-form-483-frequently-asked-questions
- fda.gov · Source 17 ↗https://www.fda.gov/drugs/human-drug-compounding/fda-alerts-health-care-providers-compounders-and-patients-dosing-errors-associated-compounded
- fda.gov · Source 18 ↗https://www.fda.gov/drugs/drug-supply-chain-integrity/check-licensure-wholesale-drug-distributors-and-third-party-logistics-providers
- fda.gov · Source 19 ↗https://www.fda.gov/drugs/drug-supply-chain-security-act-dscsa/pharmacists-utilize-dscsa-requirements-protect-your-patients
- fda.gov · Source 20 ↗https://www.fda.gov/media/194424/download
- fda.gov · Source 21 ↗https://www.fda.gov/drugs/human-drug-compounding/fda-telehealth-companies-what-know-when-promoting-compounded-drugs
- lilly.com · Source 22 ↗https://www.lilly.com/lillydirect/faq
- lilly.com · Source 23 ↗https://www.lilly.com/lillydirect/rx-support
- zepbound.lilly.com · Source 24 ↗https://zepbound.lilly.com/hcp/coverage-savings
- novocare.com · Source 25 ↗https://www.novocare.com/hcp/delivery.html
- novocare.com · Source 26 ↗https://www.novocare.com/eligibility/delivery.html
- novocare.com · Source 27 ↗https://www.novocare.com/patient/medicines/wegovy/savings-offer.html
- foundayo.lilly.com · Source 28 ↗https://foundayo.lilly.com/coverage-savings
- fda.gov · Source 29 ↗https://www.fda.gov/news-events/press-announcements/fda-approves-first-new-molecular-entity-under-national-priority-voucher-program
- novo-pi.com · Source 30 ↗https://www.novo-pi.com/wegovy.pdf
- pi.lilly.com · Source 31 ↗https://pi.lilly.com/us/zepbound-uspi.pdf
- investor.lilly.com · Source 32 ↗https://investor.lilly.com/node/55266/pdf
- mms.mckesson.com · Source 33 ↗https://mms.mckesson.com/content/request-an-account/
- mckesson.com · Source 34 ↗https://www.mckesson.com/pharmacy-technology/pharmaceutical-ordering/drug-returns/
- cms.gov · Source 35 ↗https://www.cms.gov/medicare/coverage/prescription-drug-coverage/medicare-glp-1-bridge/information-part-d-plans
- cms.gov · Source 36 ↗https://www.cms.gov/files/document/glp-1-pharmacies-c.pdf
- cms.gov · Source 37 ↗https://www.cms.gov/files/document/glp-1-prescribers-c-1.pdf
- pharmacy.ca.gov · Source 38 ↗https://www.pharmacy.ca.gov/forms/nrp_comp_app_pkt.pdf
- pharmacy.texas.gov · Source 39 ↗https://www.pharmacy.texas.gov/applicants/new-pharmacy.asp
- telehealth.hhs.gov · Source 40 ↗https://telehealth.hhs.gov/licensure/licensing-across-state-lines
- azbn.gov · Source 41 ↗https://azbn.gov/news/fda-safety-advisory-compounded-glp-1-multi-dose-vials
- hhs.gov · Source 42 ↗https://www.hhs.gov/hipaa/for-professionals/faq/do-i-need-a-business-associate-contract-to-disclose-information-to-a-provider/index.html
- hhs.gov · Source 43 ↗https://www.hhs.gov/hipaa/for-professionals/covered-entities/sample-business-associate-agreement-provisions/index.html
- oig.hhs.gov · Source 44 ↗https://oig.hhs.gov/compliance/physician-education/fraud-abuse-laws/
- pharmacy.ca.gov · Source 45 ↗https://www.pharmacy.ca.gov/laws_regs/lawbook.pdf?preview=true&site_id=816
- ashp.org · Source 46 ↗https://www.ashp.org/-/media/assets/pharmacy-practice/resource-centers/specialty-pharmacy/Medication-Access-Coordinator.pdf
- careers.unitedhealthgroup.com · Source 47 ↗https://careers.unitedhealthgroup.com/job/jeffersonville/pharmacy-care-coordinator/34088/103216187584
- shows.acast.com · Source 48 ↗https://shows.acast.com/everything-glp-1/episodes/scott-brunner-inside-the-regulatory-battle-shaping-compounde
- youtube.com · Source 49 ↗https://www.youtube.com/watch?v=T4JNCTma9NA
- fiercehealthcare.com · Source 50 ↗https://www.fiercehealthcare.com/health-tech/hims-hers-inks-deal-eli-lilly-offer-branded-weight-loss-drugs